No Heading
Purpose.
The functional characterization of monkey OAT1 (SLC22A6) and OAT3 (SLC22A8) was carried out to elucidate species differences in the OAT1- and OAT3-mediated transport between monkey and human.
Methods.
The cDNAs of monkey OAT1 and OAT3 were isolated from monkey kidney, and their stable transfectants were established in HEK293 cells (mkOAT1- and mkOAT3-HEK). Transport studies were performed using cDNA transfectants, and kinetic parameters were compared among rat, monkey and human.
Results.
The amino acid sequences of mkOAT1 and mkOAT3 exhibit 97% and 96% identity to their corresponding human orthologues. For OAT1, there was no obvious species difference in the Km values and the relative transport activities of 11 substrates with regard to p-aminohippurate transport. For OAT3, there was no species difference in the Km values and in the relative transport activities of nine substrates with regard to benzylpenicillin transport between monkey and human. However, the relative transport activities of indoxyl sulfate, 3-carboxy-4-methyl-5-propyl-2-furanpropionate, and estrone-3-sulfate showed a difference between primates and rat and gave a poor correlation.
Conclusions.
These results suggest that monkey is a good predictor of the renal uptake of organic anions in the human.
Similar content being viewed by others
Abbreviations
- α-KG:
-
α-ketoglutarate
- ACV:
-
acyclovir
- AZT:
-
3′-azido-3′-deoxythymidine
- CMD:
-
cimetidine
- CMPF:
-
3-carboxy-4-methyl-5-propyl-2-furanpropionate
- 2,4-D:
-
2,4-dichloro-phenoxy-acetate
- DHEAS:
-
dehydroepiandrosterone sulfate
- E217βG:
-
estradiol-17β-glucuronide
- E1S:
-
estrone-3-sulfate
- HA:
-
hippurate
- HEK293:
-
human embryonic kidney
- hOAT:
-
human organic anion transporter
- IA:
-
indoleacetate
- IS:
-
indoxyl sulfate
- mkOAT:
-
monkey organic anion transporter
- MTX:
-
methotrexate
- NSAIDs:
-
nonsteroidal anti-inflammatory drugs
- OTA:
-
ochratoxin A
- PAH:
-
p-amino-hippurate
- PCG:
-
benzylpenicillin
- rOat:
-
rat organic anion transporter
- TBS-T:
-
tris-buffered saline/Tween 20
References
1. M. Komori, O. Kikuchi, T. Sakuma, J. Funaki, M. Kitada, and T. Kamataki. Molecular cloning of monkey liver cytochrome P-450 cDNAs; similarity of the primary sequences to human cytochromes P-450. Biochim. Biophys. Acta 1171;141–146 (1992).
2. T. Sakuma and T. Kamataki. A combination of monkeys and genetically engineered systems can improve the accuracy of estimations in human drug metabolism and toxicity. Drug News Perspect. 7;82–86 (1994).
3. K. Ohta, M. Kitada, T. Hashizume, M. Komori, H. Ohi, and T. Kamataki. Purification of cytochrome P-450 from polychlorinated biphenyl-treated crab-eating monkeys; high homology to a form of human cytochrome P-450. Biochim. Biophys. Acta 996;142–145 (1989).
4. J. E. Sharer, L. A. Shipley, M. R. Vandenbranden, S. N. Binkley, and S. A. Wrighton. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab. Dispos. 23;1231–1241 (1995).
5. J. C. Stevens, L. A. Shipley, J. R. Cashman, M. Vandenbranden, and S. A. Wrighton. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metab. Dispos. 21;753–760 (1993).
6. J. H. Lin. Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. 23;1008–1021 (1995).
7. R. Dedrick, K. B. Bischoff, and D. S. Zaharko. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother. Rep. 54;95–101 (1970).
8. H. Matsushita, H. Suzuki, Y. Sugiyama, Y. Sawada, T. Iga, M. Hanano, and Y. Kawaguchi. Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals. J. Pharmacobiodyn. 13;602–611 (1990).
9. I. Mahmood. Interspecies scaling of renally secreted drugs. Life Sci. 63;2365–2371 (1998).
10. M. Hosoyamada, T. Sekine, Y. Kanai, and H. Endou. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol. 276;F122–F128 (1999).
11. S. H. Cha, T. Sekine, J. I. Fukushima, Y. Kanai, Y. Kobayashi, T. Goya, and H. Endou. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol. 59;1277–1286 (2001).
12. A. Enomoto, M. Takeda, M. Shimoda, S. Narikawa, Y. Kobayashi, T. Yamamoto, T. Sekine, S. H. Cha, T. Niwa, and H. Endou. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J. Pharmacol. Exp. Ther. 301;797–802 (2002).
13. H. Motohashi, Y. Sakurai, H. Saito, S. Masuda, Y. Urakami, M. Goto, A. Fukatsu, O. Ogawa, and K. Inui. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol. 13;866–874 (2002).
14. T. Deguchi, H. Kusuhara, A. Takadate, H. Endou, M. Otagiri, and Y. Sugiyama. Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int. 65;162–174 (2004).
15. M. Hasegawa, H. Kusuhara, H. Endou, and Y. Sugiyama. Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat. J. Pharmacol. Exp. Ther. 305;1087–1097 (2003).
16. M. Hasegawa, H. Kusuhara, D. Sugiyama, K. Ito, S. Ueda, H. Endou, and Y. Sugiyama. Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J. Pharmacol. Exp. Ther. 300;746–753 (2002).
17. Y. Nagata, H. Kusuhara, S. Hirono, H. Endou, and Y. Sugiyama. Carrier-mediated uptake of H2-receptor antagonists by the rat choroid plexus; involvement of rat organic anion transporter 3. Drug Metab. Dispos. 32;1040–1047 (2004).
18. W. Lee and R. B. Kim. Transporters and renal drug elimination. Annu. Rev. Pharmacol. Toxicol. 44;137–166 (2004).
19. D. Sugiyama, H. Kusuhara, Y. Shitara, T. Abe, P. J. Meier, T. Sekine, H. Endou, H. Suzuki, and Y. Sugiyama. Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J. Pharmacol. Exp. Ther. 298;316–322 (2001).
20. K. Yamaoka, Y. Tanigawara, T. Nakagawa, and T. Uno. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn. 4;879–885 (1981).
21. Y. Nagata, H. Kusuhara, H. Endou, and Y. Sugiyama. Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol. Pharmacol. 61;982–988 (2002).
22. K. Ichida, M. Hosoyamada, H. Kimura, M. Takeda, Y. Utsunomiya, T. Hosoya, and H. Endou. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int. 63;143–155 (2003).
23. H. Kusuhara, T. Sekine, N. Utsunomiya-Tate, M. Tsuda, R. Kojima, S. H. Cha, Y. Sugiyama, Y. Kanai, and H. Endou. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J. Biol. Chem. 274;13675–13680 (1999).
24. A. Aslamkhan, Y. H. Han, R. Walden, D. H. Sweet, and J. B. Pritchard. Stoichiometry of organic anion/dicarboxylate exchange in membrane vesicles from rat renal cortex and hOAT1-expressing cells. Am. J. Physiol. Renal Physiol. 285;F775–F783 (2003).
25. A. Bakhiya, A. Bahn, G. Burckhardt, and N. Wolff. Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell. Physiol. Biochem. 13;249–256 (2003).
26. D. H. Sweet, L. M. Chan, R. Walden, X. P. Yang, D. S. Miller, and J. B. Pritchard. Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient. Am. J. Physiol. Renal Physiol. 284;F763–F769 (2003).
27. T. Sekine, N. Watanabe, M. Hosoyamada, Y. Kanai, and H. Endou. Expression cloning and characterization of a novel multispecific organic anion transporter. J. Biol. Chem. 272;18526–18529 (1997).
28. D. H. Sweet, N. A. Wolff, and J. B. Pritchard. Expression clon-ing and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J. Biol. Chem. 272;30088–30095 (1997).
29. C. Timchalk. Comparative inter-species pharmacokinetics of phenoxyacetic acid herbicides and related organic acids. evidence that the dog is not a relevant species for evaluation of human health risk. Toxicology 200;1–19 (2004).
30. T. M. S. Khamdang, M. Shimoda, R. Noshiro, S. Narikawa, X. L. Huang, A. Enomoto, P. Piyachaturawat, and H. Endou. Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J. Pharmacol. Sci. 94;197–202 (2004).
31. B. C. Burckhardt, S. Brai, S. Wallis, W. Krick, N. A. Wolff, and G. Burckhardt. Transport of cimetidine by flounder and human renal organic anion transporter 1. Am. J. Physiol. Renal Physiol. 284;F503–F509 (2003).
32. R. Vanholder, A. Argiles, U. Baurmeister, P. Brunet, W. Clark, G. Cohen, P. P. De Deyn, R. Deppisch, B. Descamps-Latscha, T. Henle, A. Jorres, Z. A. Massy, M. Rodriguez, B. Stegmayr, P. Stenvinkel, and M. L. Wratten. Uremic toxicity; present state of the art. Int. J. Artif. Organs 24;695–725 (2001).
33. Y. Tsutsumi, T. Deguchi, M. Takano, A. Takadate, W. E. Lindup, and M. Otagiri. Renal disposition of a furan dicarboxylic acid and other uremic toxins in the rat. J. Pharmacol. Exp. Ther. 303;880–887 (2002).
34. N. Inotsume, M. Nishimura, M. Nakano, S. Fujiyama, and T. Sato. The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. J. Clin. Pharmacol. 30;50–56 (1990).
35. H. Motohashi, Y. Uwai, K. Hiramoto, M. Okuda, and K. I. Inui. Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur. J. Pharmacol. 503;25–30 (2004).
36. J. H. Lin, L. E. Los, E. H. Ulm, and D. E. Duggan. Kinetic studies on the competition between famotidine and cimetidine in rats. Evidence of multiple renal secretory systems for organic cations. Drug Metab. Dispos. 16;52–56 (1988).
37. T. P. Schaub, J. Kartenbeck, J. Konig, H. Spring, J. Dorsam, G. Staehler, S. Storkel, W. F. Thon, and D. Keppler. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J. Am. Soc. Nephrol. 10;1159–1169 (1999).
38. R. Masereeuw, S. Notenboom, P. H. Smeets, A. C. Wouterse, and F. G. Russel. Impaired renal secretion of substrates for the multidrug resistance protein 2 in mutant transport-deficient (TR-) rats. J. Am. Soc. Nephrol. 14;2741–2749 (2003).
39. N. Mizuno, M. Suzuki, H. Kusuhara, H. Suzuki, K. Takeuchi, T. Niwa, J. W. Jonker, and Y. Sugiyama. Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. Drug Metab. Dispos. 32;898–901 (2004).
40. J. W. Jonker, M. Buitelaar, E. Wagenaar, M. A. Van Der Valk, G. L. Scheffer, R. J. Scheper, T. Plosch, F. Kuipers, R. P. Elferink, H. Rosing, J. H. Beijnen, and A. H. Schinkel. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. USA 99;15649–15654 (2002).
41. A. E. Busch, A. Schuster, S. Waldegger, C. A. Wagner, G. Zempel, S. Broer, J. Biber, H. Murer, and F. Lang. Expression of a renal type I sodium/phosphate transporter (NaPi-1) induces a conductance in Xenopus oocytes permeable for organic and inorganic anions. Proc. Natl. Acad. Sci. USA 93;5347–5351 (1996).
42. T. Imaoka, H. Kusuhara, S. Adachi-Akahane, M. Hasegawa, N. Morita, H. Endou, and Y. Sugiyama. The renal-specific transporter mediates facilitative transport of organic anions at the brush border membrane of mouse renal tubules. J. Am. Soc. Nephrol. 15;2012–2022 (2004).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tahara, H., Shono, M., Kusuhara, H. et al. Molecular Cloning and Functional Analyses of OAT1 and OAT3 from Cynomolgus Monkey Kidney. Pharm Res 22, 647–660 (2005). https://doi.org/10.1007/s11095-005-2503-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-005-2503-0